Mission DMD: FibroGen’s Anti-Fibrosis Program (February 2017)
by: Parent Project Muscular Dystrophy
Mission DMD: FibroGen’s Anti-Fibrosis Program (February 2017)
On February 1, 2017, PPMD and FibroGen hosted a webinar to discuss FibroGen’s investigational drug Pamrevlumab (FG-3019), along with FibroGen’s Mission DMD program that is currently being conducted to investigate Pamrevlumab in Duchenne.
by: Parent Project Muscular Dystrophy
